235 related articles for article (PubMed ID: 31624532)
1. Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?
Zhang C; Yu D
Cell Biosci; 2019; 9():82. PubMed ID: 31624532
[TBL] [Abstract][Full Text] [Related]
2. Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.
Oliver AJ; Lau PKH; Unsworth AS; Loi S; Darcy PK; Kershaw MH; Slaney CY
Front Immunol; 2018; 9():70. PubMed ID: 29445373
[TBL] [Abstract][Full Text] [Related]
3. Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis.
Schulz M; Salamero-Boix A; Niesel K; Alekseeva T; Sevenich L
Front Immunol; 2019; 10():1713. PubMed ID: 31396225
[TBL] [Abstract][Full Text] [Related]
4. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy.
Conway JW; Braden J; Wilmott JS; Scolyer RA; Long GV; Pires da Silva I
Front Immunol; 2022; 13():1030147. PubMed ID: 36466910
[TBL] [Abstract][Full Text] [Related]
5. Breast Tumor Metastasis and Its Microenvironment: It Takes Both Seed and Soil to Grow a Tumor and Target It for Treatment.
Bonni S; Brindley DN; Chamberlain MD; Daneshvar-Baghbadorani N; Freywald A; Hemmings DG; Hombach-Klonisch S; Klonisch T; Raouf A; Shemanko CS; Topolnitska D; Visser K; Vizeacoumar FJ; Wang E; Gibson SB
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473273
[TBL] [Abstract][Full Text] [Related]
6. Blood-Brain Barrier, Cell Junctions, and Tumor Microenvironment in Brain Metastases, the Biological Prospects and Dilemma in Therapies.
Guan Z; Lan H; Cai X; Zhang Y; Liang A; Li J
Front Cell Dev Biol; 2021; 9():722917. PubMed ID: 34504845
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
8. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
9. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
10. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
11. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.
Kim SY; Kim S; Kim JE; Lee SN; Shin IW; Shin HS; Jin SM; Noh YW; Kang YJ; Kim YS; Kang TH; Park YM; Lim YT
ACS Nano; 2019 Nov; 13(11):12671-12686. PubMed ID: 31589013
[TBL] [Abstract][Full Text] [Related]
12. TME-targeted approaches of brain metastases and its clinical therapeutic evidence.
Khan IM; Khan SU; Sala HSS; Khan MU; Ud Din MA; Khan S; Hassan SSU; Khan NM; Liu Y
Front Immunol; 2023; 14():1131874. PubMed ID: 37228619
[TBL] [Abstract][Full Text] [Related]
13. Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies.
D'Souza NM; Fang P; Logan J; Yang J; Jiang W; Li J
Front Oncol; 2016; 6():212. PubMed ID: 27774435
[TBL] [Abstract][Full Text] [Related]
14. Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.
Owyong M; Hosseini-Nassab N; Efe G; Honkala A; van den Bijgaart RJE; Plaks V; Smith BR
Drug Resist Updat; 2017 Nov; 33-35():23-35. PubMed ID: 29145972
[TBL] [Abstract][Full Text] [Related]
15. The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy.
Wo YJ; Gan ASP; Lim X; Tay ISY; Lim S; Lim JCT; Yeong JPS
Cells; 2019 Dec; 9(1):. PubMed ID: 31861847
[TBL] [Abstract][Full Text] [Related]
16. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy and tumor microenvironment.
Tang H; Qiao J; Fu YX
Cancer Lett; 2016 Jan; 370(1):85-90. PubMed ID: 26477683
[TBL] [Abstract][Full Text] [Related]
18. Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers.
Sevenich L
Front Oncol; 2019; 9():163. PubMed ID: 30941312
[TBL] [Abstract][Full Text] [Related]
19. The Janus Face of Tumor Microenvironment Targeted by Immunotherapy.
Buoncervello M; Gabriele L; Toschi E
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31484464
[TBL] [Abstract][Full Text] [Related]
20. Multimodal predictors for precision immunotherapy.
Roelofsen LM; Kaptein P; Thommen DS
Immunooncol Technol; 2022 Jun; 14():100071. PubMed ID: 35755892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
